Recent Finacing
Recent Raise
Be Biopharma develops engineered B‑cell medicines that program primary human B cells to continuously produce therapeutic proteins, advancing BE‑101 (Factor IX) and BE‑102 toward clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Be Biopharma.
